First Affirmative Financial Network Increases Position in Koninklijke Philips (NYSE:PHG)

First Affirmative Financial Network increased its stake in shares of Koninklijke Philips (NYSE:PHG) by 11.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,272 shares of the technology company’s stock after purchasing an additional 1,014 shares during the quarter. First Affirmative Financial Network’s holdings in Koninklijke Philips were worth $205,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Principal Securities Inc. purchased a new stake in Koninklijke Philips in the fourth quarter valued at about $27,000. Bruce G. Allen Investments LLC acquired a new stake in Koninklijke Philips during the 4th quarter worth about $140,000. GAMMA Investing LLC purchased a new position in shares of Koninklijke Philips during the 4th quarter valued at about $146,000. Contravisory Investment Management Inc. acquired a new position in shares of Koninklijke Philips in the 4th quarter valued at about $200,000. Finally, Capital Analysts LLC boosted its stake in shares of Koninklijke Philips by 6.3% in the fourth quarter. Capital Analysts LLC now owns 8,820 shares of the technology company’s stock worth $206,000 after buying an additional 521 shares during the last quarter. Institutional investors own 13.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on PHG shares. BNP Paribas raised Koninklijke Philips from an “underperform” rating to a “neutral” rating in a report on Tuesday, May 7th. StockNews.com upgraded shares of Koninklijke Philips from a “hold” rating to a “buy” rating in a research report on Friday, May 24th. Sanford C. Bernstein upgraded shares of Koninklijke Philips from a “market perform” rating to an “outperform” rating in a research report on Monday, May 13th. UBS Group raised shares of Koninklijke Philips from a “sell” rating to a “neutral” rating in a research note on Tuesday, April 30th. Finally, JPMorgan Chase & Co. upgraded Koninklijke Philips from an “underweight” rating to a “neutral” rating in a research note on Tuesday, April 30th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Koninklijke Philips presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Koninklijke Philips Stock Up 0.1 %

NYSE:PHG opened at $26.25 on Friday. The company’s 50-day moving average is $25.44 and its two-hundred day moving average is $22.83. Koninklijke Philips has a 1-year low of $17.75 and a 1-year high of $29.44. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings data on Monday, April 29th. The technology company reported $0.28 EPS for the quarter. The firm had revenue of $4.49 billion for the quarter. Koninklijke Philips had a positive return on equity of 9.82% and a negative net margin of 4.41%. As a group, equities analysts anticipate that Koninklijke Philips will post 1.54 earnings per share for the current fiscal year.

Koninklijke Philips Cuts Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, May 9th. Investors of record on Friday, May 10th were issued a $0.9154 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a yield of 3.5%. Koninklijke Philips’s dividend payout ratio (DPR) is currently -95.83%.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.